Back to Journals » Clinical Epidemiology » Volume 11

Association between the extent of coronary artery disease and prognosis in patients with diabetes mellitus [Letter]

Authors Xu H, Bu HJ, He JZ

Received 26 May 2019

Accepted for publication 5 July 2019

Published 13 August 2019 Volume 2019:11 Pages 723—724

DOI https://doi.org/10.2147/CLEP.S217196

Checked for plagiarism Yes

Editor who approved publication: Dr Eyal Cohen



Huan Xu, Hui-Ju Bu, Jing-Zhao He


Intensive Care Unit, Dongguan Donghua Hospital, Dongguan, Guangdong, People’s Republic of China

 

The correlation between the extent of coronary artery disease (CAD) and clinical outcomes among patients with diabetes mellitus (DM) was unclear. Recently, we read with great interest the study by Gyldenkerne et al.The authors conducted a cohort study of patients with DM who underwent coronary angiography and were stratified according to the extent of coronary artery disease: 0-, 1-, 2- or 3-vessel disease or diffuse vessel disease, with myocardial infarction, all-cause death, and major adverse cardiovascular events (MACE) as endpoints.

 

View the original paper by Gyldenkerne and colleagues

Dear editor

The correlation between the extent of coronary artery disease (CAD) and clinical outcomes among patients with diabetes mellitus (DM) was unclear. Recently, we read with great interest the study by Gyldenkerne et al.1 The authors conducted a cohort study of patients with DM who underwent coronary angiography and were stratified according to the extent of coronary artery disease: 0-, 1-, 2- or 3-vessel disease or diffuse vessel disease, with myocardial infarction, all-cause death, and major adverse cardiovascular events (MACE) as endpoints. They concluded that the extent of coronary artery disease is a significant risk factor for myocardial infarction and death in patients with DM. The research appears informative clinically. Thus, we addressed some issues regarding this study.

First, low-density lipoprotein cholesterol (LDL) plays a vital role in the perpetuation and pathogenesis of atherosclerotic CVD.2 The increased level of LDL is associated with an elevated risk of CVD events and decreasing of LDL is associated with a reduction in the event.3 Nevertheless, although the percentage of patients using statin was similar between the three groups, the LDL level was not described in the baseline characteristics. The conclusion may not be rigorous without considering this vital factor.

Second, the HbA1c level at baseline and during follow-up was associated with the risk of CVD.4 For patients with CAD and DM, the HbA1c was a routine test during the follow-up time. Unfortunately, the baseline HbA1c was not reported in the study by Gyldenkerne et al.

Third, although the coronary angiography (CAG) could not describe the lesion morphology and plaque vulnerability in the vessel wall, it could identify the lesion location and the number of lesions. Indeed, the lesion location was related to the prognosis for patients with CAD. For instance, patients with critical proximal left anterior descending may go on to develop massive anterior wall myocardial infarction. Additionally, one vessel may have more than one lesions. Therefore, the association between the extent of coronary artery disease and outcomes should be interpreted cautiously without reporting the lesion location and the number of lesions.

Fourth, more pieces of evidence showed that the major adverse cardiac events were different between the male and female in patients with CVD.5 In this study, the percentage of the male was different between the three groups. Did the authors performer the subgroup analysis based on gender?

Fifth, treatment compliance was poor in patients with CAD and DM because there are many oral drugs in these patients. In this situation, the comparison between the patients with CVD and those without CVD may be influenced by the treatment compliance.

Disclosure

The authors report no conflicts of interest in this communication.

References

1. Gyldenkerne C, Olesen KKW, Madsen M, et al. Extent of coronary artery disease is associated with myocardial infarction and mortality in patients with diabetes mellitus. Clinical Epidemiology. 2019;2019(11):419–428. doi:10.2147/CLEP.S200173

2. National Cholesterol Education Program Expert Panel on Detection E, Treatment of High Blood Cholesterol in A. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.

3. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472. doi:10.1093/eurheartj/ehx144

4. Zhao W, Katzmarzyk PT, Horswell R, Wang Y, Johnson J, Hu G. HbA1c and coronary heart disease risk among diabetic patients. Diabetes Care. 2014;37(2):428–435. doi:10.2337/dc13-1525

5. Hess CN, McCoy LA, Duggirala HJ, et al. Sex-based differences in outcomes after percutaneous coronary intervention for acute myocardial infarction: a report from TRANSLATE-ACS. J Am Heart Assoc. 2014;3(1):e000523. doi:10.1161/JAHA.114.000844

Creative Commons License © 2019 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.